ASCO GU Symposium Announces New Findings on Tumor Reduction and Survival Outcomes in Advanced Renal Cell Carcinoma
The latest analysis, presented Feb. 13-14 at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025), further solidifies the effectiveness of the lenvatinib (Lenvima) and pembrolizumab (Keytruda) combination in treating this aggressive form of kidney cancer. Hutson played a key role in the study and provided insights into the impact of these findings.
“This analysis reinforces that greater tumor shrinkage correlates with improved survival outcomes,” Hutson said. “We now have compelling evidence that reducing overall tumor burden not only extends survival but also enhances the effectiveness of subsequent treatments, setting patients up for better long-term prognoses.”
The study, which initially led to the FDA approval of lenvatinib plus pembrolizumab for advanced renal cell carcinoma in 2021, continues to provide valuable insights into treatment strategies. The new findings demonstrate that patients with greater reductions in total tumor size at disease progression had significantly longer median survival rates. Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve their IMDC risk scores, further supporting the regimen’s impact on long-term survival.
“These findings emphasize the importance of aggressive tumor reduction in the fight against renal cell carcinoma,” Hutson added. “The data suggest that this combination therapy offers the best outcomes among currently available treatments, making it a strong contender for first-line treatment in advanced renal cell carcinoma.”
TTUHSC and UMC Health System remain committed to advancing cancer treatment and improving patient outcomes through innovative research and clinical excellence.
About Texas Tech University Health Sciences Center
TTUHSC is a medical education, research and patient care leader dedicated to improving health outcomes across Texas and beyond.
About UMC Health System
UMC Health System is a nationally recognized academic medical center committed to delivering advanced patient care, innovative research and comprehensive cancer treatment.
Related Stories
TTUHSC’s Graduate School of Biomedical Sciences Hosts 37th Student Research Week
Student researchers from the Texas Tech University Health Sciences Center (TTUHSC) participated in the 37th Student Research Week Feb. 26-28.
German Joins TTUHSC’s Growing List of Senior Members for National Academy of Inventors
Nadia German, Ph.D., director of the Medicinal Chemistry program at the TTUHSC Jerry H. Hodge School of Pharmacy, has been named to the National Academy of Inventors (NAI) 2025 class of Senior Members.
ASCO GU Symposium Announces New Findings on Tumor Reduction and Survival Outcomes in Advanced Renal Cell Carcinoma
Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at TTUHSC and director of the UMC Cancer Center, shared groundbreaking findings from the landmark CLEAR study.
Recent Stories
Medical Students Meet Their Match
March represents springtime, new beginnings and time for Match Day for fourth-year medical students nationwide. The Texas Tech University Health Sciences Center’s (TTUHSC) School of Medicine students participated in Match Day Friday (March 21).
Burnout and Compassion Fatigue: Health and Human Services
Dr. Elizabeth Chavez-Palacios, LPC-S, CRC, instructor for the Clinical Rehabilitation Counseling program at TTUHSC, discussed burnout and compassion fatigue.
Psychedelic Therapy: Jury’s Still Out
Dr. Michelle Shuler, an assistant professor in the Department of Clinical Counseling and Mental Health at TTUHSC, discussed psychedelic therapy.